furan-2-carboxylic acid-(3-nitro-anilide) | 52109-85-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: furan-2-carboxylic acid-(3-nitro-anilide)
• 英文别名: Furan-2-carbonsaeure-(3-nitro-anilid)；SKI-87246；2-(m-Nitro)-furanilid；N-(3-nitrophenyl)furan-2-carboxamide
• CAS: 52109-85-0
• 化学式: C₁₁H₈N₂O₄
• mdl: MFCD00095798
• 分子量: 232.196
• InChiKey: VOVIUHCZEVLDNA-UHFFFAOYSA-N

物化性质

• 熔点：
  136 °C
• 沸点：
  283.9±20.0 °C(Predicted)
• 密度：
  1.424±0.06 g/cm3(Predicted)
• 保留指数：
  2164

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  88.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2932190090

反应信息

• 作为反应物：
  描述：

  furan-2-carboxylic acid-(3-nitro-anilide) 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 8.0h， 生成 Furan-2-carboxylic acid (3-benzoylamino-phenyl)-amide
  参考文献：
  名称：

  Potent and selective inhibitors of the TASK-1 potassium channel through chemical optimization of a bis-amide scaffold

  摘要：

  TASK-1 is a two-pore domain potassium channel that is important to modulating cell excitability, most notably in the context of neuronal pathways. In order to leverage TASK-1 for therapeutic benefit, its physiological role needs better characterization; however, designing selective inhibitors that avoid the closely related TASK-3 channel has been challenging. In this study, a series of bis-amide derived compounds were found to demonstrate improved TASK-1 selectivity over TASK-3 compared to reported inhibitors. Optimization of a marginally selective hit led to analog 35 which displays a TASK-1 IC50=16 nM with 62-fold selectivity over TASK-3 in an orthogonal electrophysiology assay.

  DOI：

  10.1016/j.bmcl.2014.06.032
• 作为产物：
  描述：

  糠酸（呋喃甲酸） 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 furan-2-carboxylic acid-(3-nitro-anilide)
  参考文献：
  名称：

  噻吩和呋喃的芳香族化合物的核磁共振波谱分析法测定噻吩和呋喃的芳香指数

  摘要：

  一系列的米-和p -取代的苯甲酸，2-噻吩甲酸，和2-糠酸酰替苯胺的制备和它们的1 H和13 C NMR光谱特性进行了研究。通常，在酰基芳香环的质子和碳信号的化学位移与Hammettσ之间观察到良好的相关性。在二甲亚砜-d 6中，苯甲酰苯胺的羰基碳的化学位移值与2-硫代酰胺和2-呋喃酰胺的化学位移图具有极好的相关性，其斜率值分别为0.79和0.52 。该斜率可以被认为是一组芳香性指数。

  DOI：

  10.1002/jhet.5570390616

文献信息

• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。
• PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS
  申请人：Djaballah Hakim

  公开号：US20100210649A1

  公开（公告）日：2010-08-19

  The present invention is directed to pyridazinone compounds of formula (I) and furan compounds of formula (II), pharmaceutical compositions of compounds of formula (I) and (II), kits containing these compounds, methods of syntheses, and a method of treatment of a proliferative disease in a subject by administration of a therapeutically effective amount of a compound of formulae (I) or (II). Both classes of compounds were identified through screening of a collection of small molecule libraries.

  本发明涉及式(I)的吡啶二酮化合物和式(II)的呋喃化合物，以及式(I)和(II)化合物的制药组合物、包含这些化合物的试剂盒、合成方法，以及通过给予式(I)或(II)化合物的治疗有效量来治疗受体内增生性疾病的方法。这两类化合物是通过筛选小分子库的集合而确定的。
• Aromatic amines and methods for their preparation
  申请人：DU PONT

  公开号：US02144220A1

  公开（公告）日：1939-01-17
• Acylthiourea, Acylurea, and Acylguanidine Derivatives with Potent Hedgehog Inhibiting Activity
  作者：Antonio Solinas、Hélène Faure、Hermine Roudaut、Elisabeth Traiffort、Angèle Schoenfelder、André Mann、Fabrizio Manetti、Maurizio Taddei、Martial Ruat

  DOI：10.1021/jm2013369

  日期：2012.2.23

  The Smoothened (Smo) receptor is the major transducer of the Hedgehog (Hh) signaling pathway. On the basis of the structure of the acylthiourea Smo antagonist (MRT-10), a number of different series of analogous compounds were prepared by ligand-based structural optimization. The acylthioureas, originally identified as actives, were converted into the corresponding acylureas or acylguanidines. In each series, similar structural trends delivered potent compounds with IC50 values in the nanomolar range with respect to the inhibition of the Hh signaling pathway in various cell-based assays and of BODIPY-cyclopamine binding to human Smo. The similarity of their biological activities, in spite of discrete structural differences, may reveal the existence of hydrogen-bonding interactions between the ligands and the receptor pocket. Biological potency of compounds 61, 72, and 86 (MRT-83) were comparable to those of the clinical candidate GDC-0449. These findings suggest that these original molecules will help delineate Smo and Hh functions and can be developed as potential anticancer agents.
• Facile and Effective Synthesis of N-Aryl-2-Furancarboxamides Derivatives Under the Condition of Phase Transfer Catalysis
  作者：Tai-Bao Wei、You-Ming Zhang

  DOI：10.1080/00397919908086466

  日期：1999.9

  A convenient one-pot procedure is reported for the preparation of N-aryl-2-furancarboxamide derivatives. 2-Furoic acid is activated by benzenesulfonyl chloride under the condition of solid-liquid phase transfer catalysis using solid potassium carbonate as base and polyethylene glycol-400-(PEG-400) as phase transfer catalyst.